Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting | Zendy

Lélia Abad | Zendy; Virginie Tafani | Zendy; Jason Tasse | Zendy; Jérôme Josse | Zendy; Christian Chidiac | Zendy; Sébastien Lustıg | Zendy; Tristan Ferry | Zendy; Alan Diot | Zendy; Frédéric Laurent | Zendy; Florent Valour | Zendy

Open Access

Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting

Author(s) -

Lélia Abad,

Virginie Tafani,

Jason Tasse,

Jérôme Josse,

Christian Chidiac,

Sébastien Lustıg,

Tristan Ferry,

Alan Diot,

Frédéric Laurent,

Florent Valour

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky473

Subject(s) - linezolid , staphylococcus aureus , microbiology and biotechnology , biofilm , joint infections , methicillin resistant staphylococcus aureus , medicine , staphylococcal infections , biology , vancomycin , bacteria , surgery , genetics , periprosthetic , arthroplasty

Prolonged use of linezolid for bone and joint infection (BJI) is limited by its long-term toxicity. The better safety profile of tedizolid, a recently developed oxazolidinone, could offer an alternative. However, its efficacy against biofilm-embedded and intracellular Staphylococcus aureus, the two main bacterial reservoirs associated with BJI chronicity, is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research